| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 28, 2017Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure
DUBLIN and BARCELONA - August 28, 2017 - Medtronic plc (NYSE:MDT) today announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a...
-
Mar 30, 2014Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry Presented at ACC.14
MINNEAPOLIS and WASHINGTON, D.C. - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global...
-
Mar 29, 2014Medtronic Commits to Further Clinical Investigation and Determining Path Forward for Next U.S. IDE with FDA
MINNEAPOLIS and WASHINGTON, DC - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the full results of the SYMPLICITY HTN-3 clinical trial, which were presented today in late-breaking...
-
Jan 9, 2014
MINNEAPOLIS - January 9, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet...
-
Dec 17, 2013
Thomson Reuters ONE via COMTEX) --Medtronic's Second Randomized, Controlled Renal Denervation Clinical Trial in the U.S. Will Potentially Expand Access to the Symplicity(TM) Renal Denervation...
-
Dec 5, 2013
Thomson Reuters ONE via COMTEX) --Multi-Electrode System Built Upon Clinical Success and Strong Safety Profile of Single-Electrode Symplicity(TM) Renal Denervation System MINNEAPOLIS -- December...
-
Nov 5, 2013
Thomson Reuters ONE via COMTEX) --SYMPLICITY HTN-4 Will Potentially Expand Access for Additional Patients at Risk for Cardiovascular Complications Related to Uncontrolled Hypertension MINNEAPOLIS...
-
Oct 30, 2013
Thomson Reuters ONE via COMTEX) --Longest-term data from the first randomized, controlled trial of renal denervation presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT)...
-
Oct 17, 2013
(Thomson Reuters ONE via COMTEX) --Late Breaking Clinical Trial Features the First U.S. Data of Novel Self-Expanding Transcatheter Valve at Premier Interventional Cardiology Meeting Other...
-
Sep 3, 2013
Thomson Reuters ONE via COMTEX) --Final Clinical Outcomes from First and Longest-Running Renal Denervation Clinical Study Presented During European Society of Cardiology Congress and Accepted for...
-
Sep 2, 2013
(Thomson Reuters ONE via COMTEX) --Six and 12-Month Data from Largest Real-World Patient Population Consistent with Symplicity Randomized Clinical Trial MINNEAPOLIS and AMSTERDAM - September 2,...
-
May 23, 2013Milestone Marks a Critical Step Forward in Bringing Renal Denervation to Patients in the U.S.
MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT), today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity(TM) renal...
-
May 21, 2013First Look at Data from Global SYMPLICITY Registry Shows Renal Denervation with the Symplicity(TM) System Meets Performance Expectations in Real-World Setting
MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT), announced today the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation...
-
May 21, 2013Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time
MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation...
-
Mar 10, 201324-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology
MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...
-
Mar 7, 2013IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment
MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
-
Mar 6, 2013FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements
MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...
-
Dec 17, 2012Published data demonstrate the Symplicity(TM) renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months
MINNEAPOLIS - December 17, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were...
-
Sep 12, 2012Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People
MINNEAPOLIS - September 12, 2012 - Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Feb 13, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 13, 2012-- Medtronic, Inc. (NYSE: MDT) announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s...
-
Nov 4, 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) -- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT)...
-
Oct 26, 2011U.S. Clinical Trial of Symplicity(R) Renal Denervation System(TM) Enrolls First Patient
MINNEAPOLIS, Oct 26, 2011 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity(R) Renal Denervation...
-
Jul 11, 2011Patient Enrollment in U.S. Clinical Trial of Renal Denervation with Symplicity(R) Catheter System(TM) for Treating Resistant Hypertension to Start Soon
MINNEAPOLIS, Jul 11, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY...